Clinical Trial Details

USOR 18232

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast and Gynecologic Malignancies

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Breast Cancer
Study Type: Interventional
Phase: II
Study Start Date: 02/06/2019
Study Completion Date: 07/2022

This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AB928 in combination with pegylated liposomal doxorubicin (PLD) with or without IPI-549, or AB928 in combination with nanoparticle albumin-bound-paclitaxel (NP) in participants with advanced metastatic triple-negative breast cancer or ovarian cancer.

 

NCT Number

NCT03719326

Principal Investigator(s)

John Wallmark, MD

Sponsor(s)

Arcus Biosciences, Inc.

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female